08 Dec 2016 Compugen Discloses its Cancer Immunotherapy Program Targeting TIGIT Immune Checkpoint
08 Dec 2016 Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA
07 Dec 2016 KEYTRUDA® (pembrolizumab) Demonstrated Improved Health-Related Quality of Life Compared to Chemotherapy in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
07 Dec 2016 Alopexx Oncology Presents Encouraging Results Of A Phase I Study Of DI-Leu16-IL2 In Relapsed/Refractory NHL At The American Society Of Hematology Annual Meeting
07 Dec 2016 Novartis' Lucentis® received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions
07 Dec 2016 FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer
06 Dec 2016 Immunomedics Introduces New Antibody-Drug Conjugate at Annual Meeting of American Society of Hematology
06 Dec 2016 XBiotech Completes Enrollment in Global Phase I/II Study for its True Human™ Antibody Treatment for Serious Staphylococcus aureus Infections
06 Dec 2016 Sutro ADC Targeting CD74 Exhibits Potent Anti-tumor Activity in Multiple Malignant Cell Lines and Animal Models of Non-Hodgkin Lymphoma and Multiple Myeloma
06 Dec 2016 Opdivo (nivolumab) Alone or Combined With Yervoy (ipilimumab) Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer, From Phase 1/2 Study CheckMate -032
06 Dec 2016 Affimed Presents New Preclinical Data on Bi- and Trispecific Immune Cell Engagers at ASH
06 Dec 2016 Actinium Highlights Results from Phase 1 Clinical Trial of Actimab-A at 58th American Society of Hematology Annual Meeting
06 Dec 2016 MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 2016 Conference
06 Dec 2016 MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016
06 Dec 2016 Preclinical Data on IMGN632, a Novel CD123-Targeting ADC, Presented at ASH Annual Meeting
06 Dec 2016 Encouraging data of Indatuximab Ravtansine (BT-062) in combination therapy in advanced Multiple Myeloma
06 Dec 2016 Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting
05 Dec 2016 Seattle Genetics Highlights Phase 1 Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Including Combination Therapy with HMAs, in Patients with Acute Myeloid Leukemia at ASH Annual Meeting
05 Dec 2016 Sanofi Genzyme Announces Start of Phase III Study of Isatuximab for Relapsed and Refractory Multiple Myeloma
05 Dec 2016 Celldex Presents Data on CDX-1140, a Novel CD40 Agonist Antibody for Hematologic and Solid Malignancies, at the American Society of Hematology (ASH) Annual Meeting
05 Dec 2016 Acceleron and Celgene Announce Preliminary Results from an Investigator Initiated Phase 2 Study of Sotatercept in Myelofibrosis at the 58th Annual Meeting of the American Society of Hematology
05 Dec 2016 Mersana Presents Updated Data on Investigational Cancer Antibody Drug Conjugate at World Conference on Lung Cancer
05 Dec 2016 Celltrion Healthcare Presents Positive Results for CT-P10, Biosimilar Rituximab Candidate, in Newly Diagnosed Advanced Stage Follicular Lymphoma
05 Dec 2016 Encouraging Survival Observed With Opdivo (nivolumab) Plus Yervoy (ipilimumab) With Longer Follow-up in First-line Advanced Non-small Cell Lung Cancer, in Updated Phase 1b CheckMate -012 Study
05 Dec 2016 Aduro Biotech Announces Anti-CD27 Agonist, an Investigational Anti-Cancer Immunotherapy, Advancing in Collaboration with MSD

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing